Insider Selling: Outset Medical (NASDAQ:OM) CFO Sells $19,943.77 in Stock

Outset Medical, Inc. (NASDAQ:OM) CFO Renee Gaeta sold 4,543 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $4.39, for a total value of $19,943.77. Following the completion of the sale, the chief financial officer directly owned 180,840 shares of the company’s stock, valued at $793,887.60. This represents a 2.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Renee Gaeta also recently made the following trade(s):

• On Wednesday, June 3rd, Renee Gaeta sold 17,672 shares of Outset Medical stock. The stock was sold at an average price of $4.94, for a total transaction of $87,299.68.

Outset Medical Stock Performance

OM stock traded down $0.33 during mid-day trading on Tuesday, reaching $4.18. 143,860 shares of the stock traded hands, compared to its average volume of 407,222. The company has a quick ratio of 4.11, a current ratio of 5.19 and a debt-to-equity ratio of 1.03. Outset Medical, Inc. has a 52 week low of $3.00 and a 52 week high of $16.16. The business has a 50-day moving average of $4.58 and a two-hundred day moving average of $4.24. The firm has a market capitalization of $78.57 million, a PE ratio of -1.02 and a beta of 1.96.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%.The company had revenue of $31.64 million during the quarter, compared to analyst estimates of $28.97 million. As a group, equities analysts predict that Outset Medical, Inc. will post -3.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. BML Capital Management LLC grew its stake in shares of Outset Medical by 250.2% during the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock worth $7,304,000 after purchasing an additional 1,359,021 shares during the period. Millennium Management LLC grew its position in shares of Outset Medical by 165.8% during the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after buying an additional 262,874 shares during the period. Ensign Peak Advisors Inc increased its stake in shares of Outset Medical by 71.8% in the 4th quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock valued at $2,078,000 after acquiring an additional 234,082 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Outset Medical by 391.3% in the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after acquiring an additional 176,870 shares during the period. Finally, Alyeska Investment Group L.P. raised its position in shares of Outset Medical by 10.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock valued at $22,798,000 after acquiring an additional 150,000 shares during the period.

Wall Street Analyst Weigh In

OM has been the topic of a number of analyst reports. Weiss Ratings upgraded Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. TD Cowen restated a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Finally, Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a report on Saturday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.00.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long?term care facilities and emergency response scenarios.